Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the... see more

TSX:EDT - Post Discussion

Spectral Medical Inc > More evidence ! PMX & Covid-19
View:
Post by mercedesman on Sep 08, 2022 3:26pm

More evidence ! PMX & Covid-19

Published Aug 24, 2022

The Characteristics of Patients with Severe COVID-19 Pneumonia Treated with Direct Hemoperfusion Using Polymyxin B-Immobilized Fiber Column (PMX-DHP)

...


Conclusions This study shows that the P/F ratio, RR, and lymphocyte counts were improved early in patients with severe COVID-19 receiving PMX-DHP therapy. PMX-DHP therapy, in addition to steroids and immunomodulators, may improve oxygenation and alleviate tachypnea by modulating the lymphocyte counts and the levels of various mediators. An early increase in lymphocyte counts after PMX-DHP therapy may indicate a positive clinical outcome. Thus, performing PMX-DHP therapy before multi-organ dysfunction and lung injury have progressed may improve disease outcomes in patients with COVID-19 pneumonia.


https://www.dovepress.com/getfile.php?fileID=83293
Comment by mercedesman on Sep 08, 2022 3:31pm
6.5 million have died from Covid-19 ...so far. Perhaps some portion of those could have been helped with PMX/EAA? Still about 400 a day are dying in the USA ! As the evidence continues to mount, perhaps "the Analysts" will add another $ 1B USD to the valuation/present value of future cash flows? That's about $ 4 CAD/sh. MM
Comment by jonnieboy on Sep 08, 2022 4:45pm
Did you mean the 1 analyst that is covering EDT ? 
Comment by mercedesman on Sep 09, 2022 10:36am
ya sorry.  the one thatSeto has ties to that keeps dropping their target price* despite a plethora of good news of late, and growing future revenue opportunities, and increasing odds of completing  the remaining 1 and 1/2 FDA approvals.  *albeit at almost 5 times the current SP  MM   
Comment by Gorf79 on Sep 09, 2022 11:14am
MM I'm not even sure there is continuing analyst coverage. Unless we missed an update on The ARC and VA deals as well as FDA Breakthrough Designation. You'd have to try really, really, really hard to remain valued as an obscure and anonymous little Canadian drug making micro cap after that string of news releases. Really hard! But option season is coming...And they own it all!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

Dealroom for high-potential pre-IPO opportunities